Abstract
Background: Tenosynovial giant cell tumor refers to a group of rarely occurring tumors that are formed in the joints, which are characterized by pain, swelling, and limitation of movement of the joint. Surgery is the main treatment strategy, but the tumor is likely to recur, especially in pigmented villonodular synovitis, which is the diffuse-type giant cell tumor. Pexidartinib was approved in August 2019 by the Food and Drug Administration (FDA) with a brand name TURALIO as the first systemic approved therapy for patients having Tenosynovial Giant Cell Tumors (TGCT).
Objective: In this review, different aspects pertaining to pexidartinib have been summarized, including the pathophysiology of TGCT, chemistry, pharmacokinetics and pharmacodynamics of pexidartinib. Special attention is given to various reported clinical trials of pexidartinib.
Methods: A comprehensive literature search was conducted in the relevant databases to identify studies published in this field during recent years.
Conclusion: Pexidartinib acts by inhibiting the Colony-Stimulating Factor (CSF1)/CSF1 receptor pathway, which leads to the inhibition of the cell lines proliferation and promotes the autophosphorylation process of the ligand-induced CSF1 receptor. Pexidartinib emerged as a potential drug candidate for the treatment of TGCT.
Keywords: Tenosynovial giant cell tumor, CSF, CSF1 receptors, pexidartinib, clinical trials, cell line proliferation.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review
Volume: 21 Issue: 12
Author(s): Yunes M.M.A. Alsayadi and Pooja A. Chawla*
Affiliation:
- Department of Pharmaceutical Chemistry & Analysis, ISF College of Pharmacy, G.T. Road, Moga-142 001, Punjab,India
Keywords: Tenosynovial giant cell tumor, CSF, CSF1 receptors, pexidartinib, clinical trials, cell line proliferation.
Abstract:
Background: Tenosynovial giant cell tumor refers to a group of rarely occurring tumors that are formed in the joints, which are characterized by pain, swelling, and limitation of movement of the joint. Surgery is the main treatment strategy, but the tumor is likely to recur, especially in pigmented villonodular synovitis, which is the diffuse-type giant cell tumor. Pexidartinib was approved in August 2019 by the Food and Drug Administration (FDA) with a brand name TURALIO as the first systemic approved therapy for patients having Tenosynovial Giant Cell Tumors (TGCT).
Objective: In this review, different aspects pertaining to pexidartinib have been summarized, including the pathophysiology of TGCT, chemistry, pharmacokinetics and pharmacodynamics of pexidartinib. Special attention is given to various reported clinical trials of pexidartinib.
Methods: A comprehensive literature search was conducted in the relevant databases to identify studies published in this field during recent years.
Conclusion: Pexidartinib acts by inhibiting the Colony-Stimulating Factor (CSF1)/CSF1 receptor pathway, which leads to the inhibition of the cell lines proliferation and promotes the autophosphorylation process of the ligand-induced CSF1 receptor. Pexidartinib emerged as a potential drug candidate for the treatment of TGCT.
Export Options
About this article
Cite this article as:
Alsayadi M.M.A. Yunes and Chawla A. Pooja *, Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review, Anti-Cancer Agents in Medicinal Chemistry 2021; 21 (12) . https://dx.doi.org/10.2174/1871520620999201102123555
DOI https://dx.doi.org/10.2174/1871520620999201102123555 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cyclophilin A as a Target of Cisplatin Chemosensitizers
Current Cancer Drug Targets Targeting Ion Channels for New Strategies in Cancer Diagnosis and Therapy
Current Clinical Pharmacology Recent Advances in PUVA Photochemotherapy and PDT for the Treatment of Cancer
Current Pharmaceutical Design Combinations of Plant Polyphenols & Anti-Cancer Molecules: A Novel Treatment Strategy for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Anti-inflammatory, Antioxidant, Lung and Liver Protective Activity of <i>Galaxaura oblongata</i> as Antagonistic Efficacy against LPS using Hematological Parameters and Immunohistochemistry as Biomarkers
Cardiovascular & Hematological Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Cancer Therapy Reviews Review of the Phytochemistry and Biological Activity of Cissus incisa Leaves
Current Topics in Medicinal Chemistry Looking at Drug Resistance Mechanisms for Microtubule Interacting Drugs: Does TUBB3 Work?
Current Cancer Drug Targets TGF-β2 Signaling in High-Grade Gliomas
Current Pharmaceutical Biotechnology Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Orthotopic Liver Transplantation in Alcoholic Liver Disease Patients
Reviews on Recent Clinical Trials The Application of Natural Products in Cancer Therapy by Targeting Apoptosis Pathways
Current Drug Metabolism Research Progress on the Antitumor Effects of Rhein: Literature Review
Anti-Cancer Agents in Medicinal Chemistry Advances in Drug Discovery against Neglected Tropical Diseases: Human African and American Trypanosomiasis
Current Medicinal Chemistry Prospects of Bacteriotherapy with Nanotechnology in Nanoparticledrug Conjugation Approach for Cancer Therapy
Current Medicinal Chemistry Resveratrol-Mediated Reversal of Tumor Multi-Drug Resistance
Current Drug Metabolism The Recent Development of Farnesyltransferase Inhibitors as Anticancer and Antimalarial Agents
Mini-Reviews in Medicinal Chemistry Blockade of Jagged/Notch Pathway Abrogates Transforming Growth Factor β2-Induced Epithelial-Mesenchymal Transition in Human Retinal Pigment Epithelium Cells
Current Molecular Medicine Bioactive Triterpenic Acids: From Agroforestry Biomass Residues to Promising Therapeutic Tools
Mini-Reviews in Organic Chemistry Therapeutic Potential of Mucoadhesive Drug Delivery Systems - An Updated Patent Review
Recent Patents on Drug Delivery & Formulation